ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/Fluorouracil
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/Fluorouracil
37
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
+ Fluorouracil
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07490301
Advanced
Phase 2 / Phase 3
Recruiting
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (
M25-288
)
anti-cMET antibody-drug conjugate
+ Fluorouracil
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07431281
Advanced
Phase 3
Recruiting
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (
D9803C00001
)
anti-CLDN18.2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
fluoropyrimidine
+ Fluorouracil
Gastric cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (SUSPENDED)
ACT
2605 - Garran - The Canberra Hospital (WITHDRAWN)
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07415031
Advanced
Phase 2
Recruiting
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503) (
CA239-0071
)
KRAS G12C inhibitor,OFF-state inhibitor
+ Fluorouracil
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
NCT07277270
Advanced
Phase 1
Recruiting
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
+ Fluorouracil
Colorectal adenocarcinoma
Prostate cancer
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
NCT07276399
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (
OrigAMI-5
)
anti-PD-1 monoclonal antibody
bispecific cMET/EGFR antibody
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07197827
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors. (
YL242-INT-101-01
)
antibody-drug conjugate,VEGF-targeting
+ Fluorouracil
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06997497
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) (
1084-012
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
+ Fluorouracil
Colon adenocarcinoma
Rectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06901531
Advanced
Phase 3
Recruiting
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive (
LUCERNA
)
anti-CLDN18.2 monoclonal antibody
anti-PD-1 monoclonal antibody
+ Fluorouracil
Gastroesophageal junction adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06820463
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer (
AndroMETa-CRC
)
anti-cMET antibody-drug conjugate
+ Fluorouracil
Colorectal cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ Fluorouracil
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
+ Fluorouracil
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
+ Fluorouracil
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06741644
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors (
CS2009-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
+ Fluorouracil
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
+ Fluorouracil
Gastric cancer
Gastroesophageal cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06538610
Advanced
NA
Recruiting
Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy (
CTNZ-2022-08
)
fluoropyrimidine
+ Fluorouracil
Gastrointestinal cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06535607
Advanced
Phase 2
Recruiting
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors (
eVOLVE-02
)
bispecific PD-L1/CTLA4 antibody
+ Fluorouracil
Cervical cancer
Head and neck squamous cell carcinoma
Oesophageal squamous cell carcinoma
Pleural mesothelioma
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
+ Fluorouracil
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
+ Fluorouracil
Biliary tract cancer
Gastric cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
+ Fluorouracil
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor,OFF-state inhibitor
+ Fluorouracil
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - New Zealand Clinical Research (COMPLETED)
ACTRN12626000525381
Curative
Not Applicable
Not yet recruiting
Comparing the effect of Diversion or Intestinal stenting followed by Neoadjuvant systemic chemotherapy versus upfront surGery for Obstructing colon cancer (
DINGO
) on peritoneal disease recurrence: a multicentre open-label randomised controlled trial
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Solid tumour
ACTRN12625000583448
Radonc
Phase 2
Recruiting
Total Neoadjuvant Therapy for Organ Preservation in Early-Stage Low Rectal Cancer: The EARLY-TNT Trial (
EARLY-TNT-Trial
)
Capecitabine
Fluorouracil
Leucovorin
Oxaliplatin
Radiotherapy
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Rectal adenocarcinoma
ACTRN12624000911594
Advanced
Phase 3
Not yet recruiting
CICAFU
Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)
fluoropyrimidine
+ Fluorouracil
Skin cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ Fluorouracil
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
ACTRN12623001301651
Curative
Not Applicable
Recruiting
GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (
GeneScreen-5-FU
)
fluoropyrimidine
+ Fluorouracil
Cancer
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
+ Fluorouracil
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622000180718
Curative
Not Applicable
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
+ Fluorouracil
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
+ Fluorouracil
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12617001571369
Radonc
Not yet recruiting
Effect of Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy on survival rates: SUPER trial.
radiotherapy
+ Fluorouracil
Cancer
Pancreatic cancer
ACTRN12616000554460
Curative
Phase 1
Not yet recruiting
ACES
: Adjuvant Chemotherapy in Early stage oeSophageal cancer- a feasibility study
Cisplatin
Fluorouracil
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Oesophageal cancer
ACTRN12611000339954
Curative
Phase 3
Recruiting
Prospective Randomised Trial Of Extended Chemotherapy During The “Wait Period” Following Pre-Operative Neoadjuvant Chemoradiotherapy For Rectal Cancer (
WAIT-study
)
Fluorouracil
Leucovorin
Radiotherapy
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
+ Fluorouracil
Rectal adenocarcinoma
ACTRN12610000856011
Radonc
Phase 2
Not yet recruiting
The efficacy and safety of combined neoadjuvant chemotherapy with docetaxel, cisplatin and 5-Fluorouracil (5-FU) [TPF regimen] and concurrent chemoradiation in treating patients with locally advanced cancer of the larynx (
NA
)
fluoropyrimidine
platinum-based antineoplastic agent
taxane
+ Fluorouracil
Cancer
Head and neck cancer
ACTRN12610000776000
Advanced
Not Applicable
Recruiting
The use of novel protein biomarkers in predicting clinical outcomes in patients with localised and metastatic colorectal cancer
Fluorouracil
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
+ Fluorouracil
Colorectal cancer
ACTRN12609000504213
Curative
Not Applicable
Recruiting
Cardiac monitoring with echocardiogram and tissue doppler imaging (TDI) and serum biomarkers to assess for cardiotoxicity with anthracyclines in women during adjuvant chemotherapy for breast cancer. (
ECHO
)
Cyclophosphamide
Docetaxel
Fluorouracil
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
taxane
+ Fluorouracil
Breast cancer
ACTRN12606000015549
Radonc
Not yet recruiting
A phase I clinical trial to assess the efficacy of treatment with SIR-Spheres microspheres in patients with liver metastases from primary cancer of the pancreas
Fluorouracil
Gemcitabine
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
+ Fluorouracil
Pancreatic cancer
ACTRN12605000119695
Advanced
Phase 2
Recruiting
Randomised Phase II trial of irinotecan with hyaluronic acid (HyCAMP) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapy (CTA 2004) ............incidence of grade 3 or 4 diarrhoea. (
HyCAMP-Phase-II
)
fluoropyrimidine
topoisomerase inhibitor
+ Fluorouracil
Colorectal cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (28)
Not yet recruiting (8)
Recruitment Country and State
NSW (21)
VIC (21)
WA (12)
QLD (11)
SA (6)
NZ (2)
ACT (2)
TAS (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (10)
Phase 2 / Phase 3 (1)
Phase 3 (11)
Trial Type
Advanced (26)
Curative (7)
Radonc (4)
Cancer Therapy Class
PD-1/PD-L1
32%
PD-1
27%
EGFR
24%
VEGF
19%
KRAS
11%
MET
11%
CLDN18.2
8%
CTLA4
8%
ERBB2
8%
TIGIT
5%
PD-L1
5%
AR
3%
B7H3
3%
androgen axis
3%
VEGFA
3%
Trop2
3%
JAK
3%
SYK
3%
Facility
3168 - Clayton - Monash Medical Centre (11)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
6150 - Murdoch - Fiona Stanley Hospital (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3066 - Epping - Northern Hospital (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
2109 - North Ryde - Macquarie University Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2605 - Garran - The Canberra Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
2170 - Liverpool - Liverpool Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
2500 - Wollongong - Wollongong Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3011 - Footscray - Footscray Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
6009 - Nedlands - One Clinical Research (2)
3004 - Melbourne, Southbank - Alfred Health (2)
5042 - Bedford Park - Flinders Medical Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3199 - Frankston - PASO Medical (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2217 - Kogarah - St George Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NZ.8011 - Christchurch - New Zealand Clinical Research (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
NA
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Gastroesophageal cancer
Pancreatobiliary cancer
Thoracic cancer
Pancreatic cancer
Gastric cancer
Oesophageal cancer
Colorectal adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Head and neck cancer
Rectal adenocarcinoma
Head and neck squamous cell carcinoma
Gastric adenocarcinoma
Biliary tract cancer
Hepatobiliary cancer
Skin cancer
Male genital cancers
Prostate cancer
Urogenital cancer
Colon adenocarcinoma
HER2-positive gastric cancer
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Mesothelioma
Oesophageal squamous cell carcinoma
Pleural mesothelioma
Viral-related cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy